Consistent to this result, the percentages of CD133+ and CD44+ cells were found to decrease with the knockdown of FAM83C-AS1 in RKO and SW620 cells marked with CD133+ or CD44+, indicating that downregulation of FAM83C-AS1 blocks the cancer stemness (Figure 2G). This evidence concerns the gene CD44 and cancer.